Skip to main content

Articles

Page 28 of 33

  1. The biological basis of cognitive impairment in parkinsonian diseases is believed to be multifactorial. We investigated the contribution of dopamine deficiency to cognition in Parkinson disease (PD) and dement...

    Authors: Marta Marquie, Joseph J Locascio, Dorene M Rentz, J Alex Becker, Trey Hedden, Keith A Johnson, John H Growdon and Stephen N Gomperts
    Citation: Alzheimer's Research & Therapy 2014 6:52
  2. Despite widespread use of second-generation cholinesterase inhibitors for the symptomatic treatment of Alzheimer’s disease (AD), little is known about the long term effects of cholinergic treatment on global c...

    Authors: Pearl Behl, Jodi D Edwards, Alexander Kiss, Krista L Lanctot, David L Streiner, Sandra E Black and Donald T Stuss
    Citation: Alzheimer's Research & Therapy 2014 6:48
  3. Subcortical hyperintensities (SHs) are radiological entities commonly observed on magnetic resonance imaging (MRI) of patients with Alzheimer’s disease (AD) and normal elderly controls. Although the presence o...

    Authors: Joel Ramirez, Alicia A McNeely, Christopher JM Scott, Donald T Stuss and Sandra E Black
    Citation: Alzheimer's Research & Therapy 2014 6:49
  4. Pathologically modified tau protein is the main feature of Alzheimer’s disease (AD) and related tauopathies. Therefore, immunotherapies that target mis-disordered tau represent a promising avenue for the disea...

    Authors: Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Rostislav Skrabana and Michal Novak
    Citation: Alzheimer's Research & Therapy 2014 6:45
  5. We have identified structural determinants on tau protein that are essential for pathological tau–tau interaction in Alzheimer’s disease (AD). These regulatory domains, revealed by monoclonal antibody DC8E8, r...

    Authors: Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Petr Novak and Michal Novak
    Citation: Alzheimer's Research & Therapy 2014 6:44
  6. This review provides perspectives on the utility of magnetic resonance imaging (MRI) as a neuroimaging approach in the development of novel treatments for Alzheimer’s disease. These considerations were generat...

    Authors: Emilio Merlo Pich, Andreas Jeromin, Giovanni B Frisoni, Derek Hill, Andrew Lockhart, Mark E Schmidt, Martin R Turner, Stefania Mondello and William Z Potter
    Citation: Alzheimer's Research & Therapy 2014 6:51
  7. The aim of this investigation was to assess the effect of galantamine, an acetylcholinesterase inhibitor and allosteric modulator of nicotinic receptors, on brain atrophy in individuals with mild cognitive imp...

    Authors: Niels D Prins, Wiesje A van der Flier, Dirk L Knol, Nick C Fox, H Robert Brashear, Jeffrey S Nye, Frederik Barkhof and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2014 6:47
  8. Alzheimer’s disease (AD) is the major cause of dementia among the elderly. Finding blood-based biomarkers for disease diagnosis and prognosis is urgently needed.

    Authors: Oscar Alzate, Cristina Osorio, Robert M DeKroon, Ana Corcimaru and Harsha P Gunawardena
    Citation: Alzheimer's Research & Therapy 2014 6:43
  9. Levels of amyloid-beta monomer and deposited amyloid-beta in the Alzheimer’s disease brain are orders of magnitude greater than soluble amyloid-beta oligomer levels. Monomeric amyloid-beta has no known direct ...

    Authors: William F Goure, Grant A Krafft, Jasna Jerecic and Franz Hefti
    Citation: Alzheimer's Research & Therapy 2014 6:42
  10. Although Alzheimer’s disease (AD) is associated with early death, its life expectancy differs greatly between patients. A better understanding of this heterogeneity may reveal important disease mechanisms unde...

    Authors: Katarina Nägga, Carina Wattmo, Yi Zhang, Lars-Olof Wahlund and Sebastian Palmqvist
    Citation: Alzheimer's Research & Therapy 2014 6:41
  11. This report summarizes the findings presented at the Alzheimer’s Research UK Conference, which was held in Oxford on 25 and 26 March 2014 and which provided an overview of current dementia research from fundam...

    Authors: Rosa M Sancho, Simon H Ridley, Laura E Phipps and Eric Karran
    Citation: Alzheimer's Research & Therapy 2014 6:40
  12. MAPT encodes for tau, the predominant component of neurofibrillary tangles that are neuropathological hallmarks of Alzheimer’s disease (AD). Genetic association of MAPT variants with late-onset AD (LOAD) risk has...

    Authors: Mariet Allen, Michaela Kachadoorian, Zachary Quicksall, Fanggeng Zou, High Seng Chai, Curtis Younkin, Julia E Crook, V Shane Pankratz, Minerva M Carrasquillo, Siddharth Krishnan, Thuy Nguyen, Li Ma, Kimberly Malphrus, Sarah Lincoln, Gina Bisceglio, Christopher P Kolbert…
    Citation: Alzheimer's Research & Therapy 2014 6:39
  13. The relevance of the cerebrospinal fluid (CSF) biomarkers for the diagnosis of Alzheimer’s disease (AD) and related disorders is clearly established. However, the question remains on how to use these data, whi...

    Authors: Sylvain Lehmann, Julien Dumurgier, Susanna Schraen, David Wallon, Frédéric Blanc, Eloi Magnin, Stéphanie Bombois, Olivier Bousiges, Dominique Campion, Benjamin Cretin, Constance Delaby, Didier Hannequin, Barbara Jung, Jacques Hugon, Jean-Louis Laplanche, Carole Miguet-Alfonsi…
    Citation: Alzheimer's Research & Therapy 2014 6:38
  14. Alzheimer’s disease (AD) is characterized by the deposition of tau and amyloid in the brain. Although the core cerebrospinal fluid (CSF) AD biomarkers amyloid β peptide 1–42 (Aβ1–42), total tau (t-tau) and phosph...

    Authors: Jon B Toledo, Ané Korff, Leslie M Shaw, John Q Trojanowski and Jing Zhang
    Citation: Alzheimer's Research & Therapy 2014 6:36
  15. Alzheimer’s disease (AD) is characterized by the formation of senile plaques and neurofibrillary tangles composed of phosphorylated Tau. Several findings suggest that correcting signal dysregulation for Tau ph...

    Authors: Yasuko Kitagishi, Atsuko Nakanishi, Yasunori Ogura and Satoru Matsuda
    Citation: Alzheimer's Research & Therapy 2014 6:35
  16. Administration of several cardiovascular drugs has an effect on dementia. We aimed to investigate whether there are differences in the use of cardiovascular medication between different dementia disorders.

    Authors: Pavla Cermakova, Seyed-Mohammad Fereshtehnejad, Kristina Johnell, Bengt Winblad, Maria Eriksdotter and Dorota Religa
    Citation: Alzheimer's Research & Therapy 2014 6:34

    The Erratum to this article has been published in Alzheimer's Research & Therapy 2014 6:63

  17. Vascular dementia is the second most common cause of dementia after Alzheimer’s disease (AD). In addition, it is estimated that almost half of all AD patients have significant cerebrovascular disease comorbid ...

    Authors: Tiffany L Sudduth, Erica M Weekman, Holly M Brothers, Kaitlyn Braun and Donna M Wilcock
    Citation: Alzheimer's Research & Therapy 2014 6:32
  18. Immunotherapy targeting amyloid-β peptide is under active clinical investigation for treatment of Alzheimer’s disease (AD). Among the hypotheses being investigated for impact on clinical outcome are the prefer...

    Authors: Hadar Feinberg, José W Saldanha, Linnea Diep, Amita Goel, Angela Widom, Geertruida M Veldman, William I Weis, Dale Schenk and Guriqbal S Basi
    Citation: Alzheimer's Research & Therapy 2014 6:31
  19. The identification of tau protein as a major constituent of neurofibrillary tangles spurred considerable effort devoted to identifying and validating pathways through which therapeutics may alleviate tau burde...

    Authors: Casey Cook, Jeannette N Stankowski, Yari Carlomagno, Caroline Stetler and Leonard Petrucelli
    Citation: Alzheimer's Research & Therapy 2014 6:29
  20. Alzheimer’s disease pathology is closely connected to the processing of the amyloid precursor protein (APP) resulting in the formation of a variety of amyloid-beta (Aβ) peptides. They are found as insoluble ag...

    Authors: Markus P Kummer and Michael T Heneka
    Citation: Alzheimer's Research & Therapy 2014 6:28
  21. Lower angiotensin-converting enzyme (ACE) activity could increase the risk of Alzheimer’s disease (AD) as ACE functions to degrade amyloid-β (Aβ). Therefore, we investigated whether ACE protein and activity le...

    Authors: Hadassa M Jochemsen, Charlotte E Teunissen, Emma L Ashby, Wiesje M van der Flier, Ruth E Jones, Mirjam I Geerlings, Philip Scheltens, Patrick G Kehoe and Majon Muller
    Citation: Alzheimer's Research & Therapy 2014 6:27
  22. Vaccination against amyloid-β protein (Aβ42) induces high levels of antibody, making it a promising strategy for treating Alzheimer’s disease (AD). One drawback in the past was that clinical trial approval was...

    Authors: Shuang Wang, Yang Yu, Shuang Geng, Dongmei Wang, Li Zhang, Xiaoping Xie, Bing Wu, Chaofan Li, Hanqian Xu, Xiaolin Li, Yanxin Hu, Lianfeng Zhang, Christoph Kaether and Bin Wang
    Citation: Alzheimer's Research & Therapy 2014 6:26
  23. The objective was to study whether α-synuclein oligomers are altered in the cerebrospinal fluid (CSF) of patients with dementia, including Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB)...

    Authors: Oskar Hansson, Sara Hall, Annika Öhrfelt, Henrik Zetterberg, Kaj Blennow, Lennart Minthon, Katarina Nägga, Elisabet Londos, Shiji Varghese, Nour K Majbour, Abdulmonem Al-Hayani and Omar MA El-Agnaf
    Citation: Alzheimer's Research & Therapy 2014 6:25
  24. The Alzheimer’s Drug Discovery Foundation’s 14th International Conference on Alzheimer’s Drug Discovery was held on 9 and 10 September in Jersey City, NJ, USA. This annual meeting highlights novel therapeutic ...

    Authors: Lauren G Friedman, Katherine Price, Rachel F Lane, Aaron J Carman, Penny A Dacks, Diana W Shineman and Howard M Fillit
    Citation: Alzheimer's Research & Therapy 2014 6:22
  25. Lewy body dementia (LBD) is the second most common neurodegenerative dementia in older adults, yet there remains a delay in diagnosis that limits healthcare providers’ ability to maximize therapeutic outcomes ...

    Authors: Yael R Zweig and James E Galvin
    Citation: Alzheimer's Research & Therapy 2014 6:21
  26. Emerging evidence suggests that decreased adult hippocampal neurogenesis represents an early critical event in the course of Alzheimer’s disease (AD). In mice, adult neurogenesis is reduced by knock-in alleles...

    Authors: Keith A Wesnes, Peter Annas, Hans Basun, Chris Edgar and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2014 6:20
  27. In this study, we evaluated the safety and pharmacodynamic effects of the Fc-inactivated anti-β-amyloid (anti-Aβ) monoclonal antibody GSK933776 in patients with mild Alzheimer’s disease and mild cognitive impa...

    Authors: Thomas Leyhe, Niels Andreasen, Monica Simeoni, Arno Reich, Christine AF von Arnim, Xin Tong, Astrid Yeo, Shahid Khan, Amy Loercher, Michelle Chalker, Charles Hottenstein, Henrik Zetterberg, Jan Hilpert and Prafull Mistry
    Citation: Alzheimer's Research & Therapy 2014 6:19
  28. This review summarises the findings and applications from neuroimaging studies in dementia with Lewy bodies (DLB), highlighting key differences between DLB and other subtypes of dementia. We also discuss the i...

    Authors: Elijah Mak, Li Su, Guy B Williams and John T O’Brien
    Citation: Alzheimer's Research & Therapy 2014 6:18
  29. TMEM106B is a transmembrane glycoprotein of unknown function located within endosome/lysosome compartments expressed ubiquitously in various cell types. Previously, the genome-wide association study (GWAS) ide...

    Authors: Jun-ichi Satoh, Yoshihiro Kino, Natsuki Kawana, Yoji Yamamoto, Tsuyoshi Ishida, Yuko Saito and Kunimasa Arima
    Citation: Alzheimer's Research & Therapy 2014 6:17
  30. The symptomatic drugs currently on the market for Alzheimer’s disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly i...

    Authors: Lars Lannfelt, Christer Möller, Hans Basun, Gunilla Osswald, Dag Sehlin, Andrew Satlin, Veronika Logovinsky and Pär Gellerfors
    Citation: Alzheimer's Research & Therapy 2014 6:16
  31. The progressive dementia that is characteristic of Alzheimer’s disease is associated with the accumulation of amyloid-beta (Aβ) peptides in extracellular plaques and within neurons. Aβ peptides are targeted to...

    Authors: Charlotte Simmons, Victoria Ingham, Alun Williams and Clive Bate
    Citation: Alzheimer's Research & Therapy 2014 6:15
  32. Many progressive neurodegenerative diseases, including Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, and frontotemporal lobe dementia, are associated with the formati...

    Authors: Faisal Fecto, Y Taylan Esengul and Teepu Siddique
    Citation: Alzheimer's Research & Therapy 2014 6:13
  33. “Partners in Dementia Care” (PDC) tested the effectiveness of a care-coordination program integrating healthcare and community services and supporting veterans with dementia and their caregivers. Delivered via...

    Authors: David M Bass, Katherine S Judge, ALynn Snow, Nancy L Wilson, Robert O Morgan, Katie Maslow, Ronda Randazzo, Jennifer A Moye, Germaine L Odenheimer, Elizabeth Archambault, Richard Elbein, Paul Pirraglia, Thomas A Teasdale, Catherine A McCarthy, Wendy J Looman and Mark E Kunik
    Citation: Alzheimer's Research & Therapy 2014 6:9
  34. Tau pathology is associated with a number of age-related neurodegenerative disorders. Few treatments have been demonstrated to diminish the impact of tau pathology in mouse models and none are yet effective in...

    Authors: Maj-Linda Selenica, Leif Benner, Steven B Housley, Barbara Manchec, Daniel C Lee, Kevin R Nash, Jay Kalin, Joel A Bergman, Alan Kozikowski, Marcia N Gordon and Dave Morgan
    Citation: Alzheimer's Research & Therapy 2014 6:12
  35. The introduction of tau imaging agents such as 18F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminary 18F-THK523-PET studies hav...

    Authors: Michelle T Fodero-Tavoletti, Shozo Furumoto, Leanne Taylor, Catriona A McLean, Rachel S Mulligan, Ian Birchall, Ryuichi Harada, Colin L Masters, Kazuhiko Yanai, Yukitsuka Kudo, Christopher C Rowe, Nobuyuki Okamura and Victor L Villemagne
    Citation: Alzheimer's Research & Therapy 2014 6:11
  36. Sports-related concussions are one of the major causes of mild traumatic brain injury. Although most patients recover completely within days to weeks, those who experience repetitive brain trauma (RBT) may be ...

    Authors: Thomas SC Ng, Alexander P Lin, Inga K Koerte, Ofer Pasternak, Huijun Liao, Sai Merugumala, Sylvain Bouix and Martha E Shenton
    Citation: Alzheimer's Research & Therapy 2014 6:10
  37. Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, afflicting more than one-third of people over the age of 85. While many therapies for AD are in late-stage clinical testing, rational drug ...

    Authors: Haakon B Nygaard, Christopher H van Dyck and Stephen M Strittmatter
    Citation: Alzheimer's Research & Therapy 2014 6:8
  38. Alzheimer’s disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protei...

    Authors: Bengt Winblad, Ana Graf, Marie-Emmanuelle Riviere, Niels Andreasen and J Michael Ryan
    Citation: Alzheimer's Research & Therapy 2014 6:7
  39. Cerebrospinal fluid (CSF) amyloid-beta 38 (Aβ38), 40 (Aβ40), 42 (Aβ42) and total tau (T-tau) are finding increasing utility as biomarkers of Alzheimer’s disease (AD). The purpose of this study was to determine...

    Authors: Jamie Toombs, Ross W Paterson, Jonathan M Schott and Henrik Zetterberg
    Citation: Alzheimer's Research & Therapy 2014 6:5
  40. Dementia is currently diagnosed based on clinical symptoms and signs, but significant brain damage has already occurred by the time a clinical diagnosis of dementia is made, and it is increasingly recognized t...

    Authors: Galit Weinstein and Sudha Seshadri
    Citation: Alzheimer's Research & Therapy 2014 6:6
  41. Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disease that occurs in association with repetitive traumatic brain injury experienced in sport and military service. In most instances,...

    Authors: Thor D Stein, Victor E Alvarez and Ann C McKee
    Citation: Alzheimer's Research & Therapy 2014 6:4
  42. Perhaps more definitively than any other class of novel Alzheimer’s disease (AD) therapy, pre-clinical studies in mouse models of amyloid β (Aβ) deposition have established the disease-modifying potential of a...

    Authors: Todd E Golde
    Citation: Alzheimer's Research & Therapy 2014 6:3